Cardinal Health Aktie News

Cardinal Health is upgraded to a buy after Q2 2026 delivered robust revenue, margin expansion, and raised full-year guidance. Q2 revenue grew 19% YoY to $65.6B, with non-GAAP EPS up 36% and broad-based segment strength, especially in pharmaceuticals. Management executed $750M in share repurchases YTD, underscoring commitment to capital return and reducing outstanding shares by 2.5%.

Cardinal Health (NYSE: CAH) delivered a decisive second-quarter beat on February 5, 2026, with non-GAAP EPS of $2.63, surpassing the $2.38 consensus estimate by 10.5%.

The pharmaceutical distributor and health services company raises its guidance for the second time.

Cardinal Health, Inc. (CAH) Q2 2026 Earnings Call Transcript

Cardinal Health on Thursday raised its expectations for annual profit after surpassing Wall Street estimates for quarterly results, as it bets on robust demand for specialty medicines and strong performance across its segments.

Cardinal Health raised its outlook for the year after logging higher profit and revenue in its fiscal second quarter.

Revenue increased 19% to $65.6 billion GAAP 1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97 Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63 Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35 Cardinal Health completes annual baseline share repurchase of $750 million ...

Dividend Aristocrats underperformed the S&P 500 in 2025, with NOBL returning 6.82% versus SPY's 17.70%. 2026 began strong for Aristocrats, with NOBL gaining 5.67% in January, outpacing SPY's 1.47%. Dividend growth for Aristocrats averaged 5.52% in 2025, but early 2026 increases trend slightly lower, raising questions for the year's outlook.